31 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
8360884	134	Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and complementary-receptor-field alignment rules.	Washington University
22541393	1	A variant peptide of buffalo colostrumß-lactoglobulin inhibits angiotensin I-converting enzyme activity.	University of Mysore
12852763	20	Computer-aided selection of potential antihypertensive compounds with dual mechanism of action.	Institute of Biomedical Chemistry of Russian Academy of Medical Sciences
10753476	84	Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities.	University of Paris
10602705	82	Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme.	University of Paris
8632427	80	Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.	University of Paris
8691458	60	Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.	University of Paris
8459398	36	1,2-Cyclomethylenecarboxylic monoamide hydroxamic derivatives. A novel class of non-amino acid angiotensin converting enzyme inhibitors.	Laboratori Guidotti
2342054	19	Angiotensin-converting enzyme inhibitors. 9. Novel [[N-(1-carboxy-3-phenylpropyl)amino]acyl]glycine derivatives with diuretic activity.	Rorer Central Research
2544729	8	Angiotensin converting enzyme inhibitors: spirapril and related compounds.	Schering-Plough
3035180	44	Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids.	TBA
3005576	27	Angiotensin converting enzyme inhibitors as antihypertensive agents: 1-[(2-mercaptocycloalkyl)carbonyl]-L-prolines.	TBA
3906131	61	Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.	TBA
2999394	21	Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.	TBA
2995670	12	Angiotensin converting enzyme inhibitors: 1,5-benzothiazepine derivatives.	TBA
6298429	31	(Mercaptopropanoyl)indoline-2-carboxylic acids and related compounds as potent angiotensin converting enzyme inhibitors and antihypertensive agents.	TBA
6298428	28	Antihypertensive agents: angiotensin converting enzyme inhibitors. 1-[3-(Acylthio)-3-aroylpropionyl]-L-prolines.	TBA
	22	Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11	TBA
	8	Studies on the structural feature of S'1 subsite of neprilysin (EC.3.4.24.11): Stereochemical requirement for the enzyme-inhibitor docking process	TBA
12113828	63	N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.	University of Paris
8360886	4	A mechanism-based inactivation study of neutral endopeptidase 24.11.	Salk Biotechnology/Industrial Associates
7562931	41	Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl alpha-ketobenzoxazoles.	Zeneca Pharmaceuticals
3430165	2	Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity.	Ehime University
2522989	14	Carboxyalkyl dipeptides with atrial natriuretic factor potentiating and antihypertensive activity.	Schering-Plough Research Institute
28810191	4	Structure-function studies of BPP-BrachyNH	Universidade Federal Do Piau£
1992145	5	Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats.	Research and Development Laboratories
28442252	62	Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome.	Ranbaxy Laboratories